Twenty out of 24 patients in arm A (venlafaxine) and 22 out of 24 patients in arm B (placebo) were assessable for neurotoxicity. Based on the NRS, full relief was more frequent in the venlafaxine arm: 31.3% versus 5.3% (P = 0.03). Venlafaxine side-effects included grade 1-2 nausea (43.1%) and asthenia (39.2%) without grade 3-4 events.
Conclusion:
Venlafaxine has clinical activity against oxaliplatin-induced acute neurosensory toxicity. Key words: neurotoxicity, oxaliplatin, venlafaxine introduction Oxaliplatin (EloxatinÒ; Sanofi Aventis Inc.) is a thirdgeneration platinum-based cytotoxic agent, widely used in colorectal cancer, in metastatic disease and in the adjuvant setting [1] [2] [3] . Moreover, oxaliplatin is being used as an alternative option to cisplatin in various cancers, such as ovarian [4] , gastric [5] or lung [6] cancer. Because of its lack of nephrotoxicity, oxaliplatin is of particular interest in the growing population of 'unfit' patients [7] [8] [9] .
Neurotoxicity is the most severe and dose-limiting cumulative toxicity resulting from oxaliplatin therapy. The neurotoxicity is not only acute, with transient symptoms including hyperpathic pain triggered by cold, but also cumulative, with increasing symptoms due to chronic peripheral sensory neuropathy. The chronic manifestations are exacerbated immediately following surgery, due to the release of the intraerythrocytic oxaliplatin pool [10] . The pathogenesis of the acute neuropathy is believed to be due to a channelopathy, involving the voltage-gated sodium channels [11] .
Venlafaxine is an antidepressant, a serotonin and a norepinephrine reuptake inhibitor; it has shown therapeutic effects for the management of chronic and neuropathic pain [12] , particularly in patients with diabetes mellitus [13] . Venlafaxine was also found, at therapeutically relevant concentrations, to block sodium channels in guinea pig ventricular myocytes [14] . We previously reported clinical activity of venlafaxine against acute neurotoxicity in a small series of patients receiving oxaliplatin [15] . We also detected preliminary evidence of activity in a patient with permanent oxaliplatin-induced neuropathy [16] .
We present here the results of the EFFOX trial, a randomized, double-blind, placebo-controlled phase III study, which aimed to evaluate the efficacy of venlafaxine for prevention and relief of acute oxaliplatin neurotoxicity.
patients and methods
This randomized, double-blind, placebo-controlled phase III trial was conducted in six University Hospitals in France. The protocol and informed consent documentation were reviewed and approved by the Independent Ethics Committee of Cochin University Hospital.
This study was conducted in compliance with the ethical principles according to the Declaration of Helsinki. Written informed consent was obtained before the subject entering the study. This trial was registered in the European Clinical Trials database under the number 2004-000590-66.
baseline and efficacy assessment
Pretreatment evaluation for patients presenting oxaliplatin-induced acute neurotoxicity was based on the 12-question form of the Neuropathic Pain Symptom Inventory (NPSI) [17] . In the NPSI, three items evaluate spontaneous ongoing pain: burning, squeezing and pressure; two items evaluate spontaneous paroxysmal pain: electric shock and stabbing; three items evaluate evoked pain: brushing, pressure and contact with something cold and two items evaluate paresthesia/dysesthesia: pins and needles and tingling. Two additional categorical items evaluate the temporal sequence of spontaneous ongoing pain (i.e. number of hours during the last 24 h). The mean intensity of each of these items during the last 24 h has to be reported on a 0-10 numeric rating scale (NRS) in which 0 is 'no pain' and 10 is 'the most intense pain imaginable'. Patients filled the NPSI from day 1 to day 5 after oxaliplatin administration. They also rated their functional impairment daily on an NRS, from 0 to 10.
Under treatment, the primary efficacy instrument was the NPSI. Each evening, from day 1 of chemotherapy until day 5, patients rated their symptoms during the previous 12 h by choosing the appropriate number from 0 to 10. They rated their functional impairment with an NRS. Finally, they also estimated the experienced relief under treatment with an NRS from 0% to 100%.
After discontinuation of treatment, neurosensory symptoms were reevaluated at 3 months using the NPSI and the oxaliplatin-specific Levi's scale [18] .
Adverse events (AE) were recorded every 2 weeks and at the end of the study.
treatment
After baseline evaluation, patients were randomly assigned to treatment according to a computer-generated random code, to receive: From day 12, no venlafaxine extended release was given in order not to overlap the dose of venlafaxine immediate release given on day 14 (day 14 = day 1 of the subsequent cycle of chemotherapy). Indeed, given the half-life of venlafaxine extended release, additional doses on day 12 and day 13 could have significantly increased the drug concentrations on day 14. Study treatment was continued as long as oxaliplatin chemotherapy lasted. When investigators stopped oxaliplatin-based chemotherapy, patients interrupted study treatment. It is unknown whether a pharmacokinetic interaction may exist between oxaliplatin and venlafaxine. However, since oxaliplatin is mainly eliminated by renal clearance, whereas venlafaxine is primarily metabolized by liver CYP2D6, the likelihood of a pharmacokinetic interaction is low. The sponsor distributed number-coded study medications to the different study sites. The sponsor, members of the study site and patients were unaware of the treatment assignment. Blinding was maintained by dispensing venlafaxine and placebo in identical capsules.
aims of the study
The primary end point was the percentage of patients with a 100% relief of acute neuropathy.
Secondary end points were percentage of responders defined as patients experienced ‡50% of relief, mean NPSI scores variations and NRS scores variations under treatment and percentage of patients with grade 0 and grade 3 neuropathy at 3 months.
statistical analysis
For the primary criterion, the study was designed to detect a difference of 25% between the proportion of patients in the placebo and venlafaxine arms, using a two-sided Fisher's exact test. The primary analysis compared proportion of patients with a 100% relief and proportion of responders between the two arms, using a two-sided Fisher's exact test. Mean scores, calculated as the mean of the five daily entries, for each question of the NPSI and for the five complementary NRS, were compared between placebo and venlafaxine groups, using a two-sided unpaired t-test. Proportion of patients with grade 0 and grade 3 neuropathy at 3 months was also compared with a two-sided Fisher's exact test.
results

patients characteristics
From October 2005 to May 2008, 54 cancer patients presenting oxaliplatin-induced acute neurotoxicity were assessed for eligibility in this trial. Six patients, however, were not included due to exclusion criteria (n = 2) and patient's decision (n = 4). Therefore, 48 patients were randomly allocated to the study treatment ( Figure 1 ). Baseline demographic and clinical characteristics were evenly distributed in the two groups (Table 1) . Median number of cycles administered at inclusion was 4.5 and mean cumulative oxaliplatin dose at inclusion was 709.8 mg in arm A and 660.5 mg in arm B. Table 2 describes the intensity of symptoms at inclusion. Pain triggered by cold, tingling, pins and needles were the most intense symptoms reported by patients in each arm.
efficacy of venlafaxine
The proportion of patients experiencing a full relief of acute neurotoxicity was significantly higher in the venlafaxine arm: 31.3% versus 5.3% (P = 0.03). Similarly, there were significantly more responder patients, experiencing a relief of ‡50%, in the venlafaxine arm: 68.8% versus 26.3% (P = 0.02).
NPSI allowed detection of a significant clinical activity of venlafaxine on pins and needles (P < 0.001) ( Table 3) . A trend in favor of venlafaxine activity on pain triggered by cold was also observed (P = 0.06). Interestingly, venlafaxine was also found to improve the functional status of the patients (P < 0.001) ( Table 3) .
A secondary end point was the occurrence of cumulative permanent neurosensory toxicity. At 3 months after the end of treatment, no patients were still under oxaliplatin-based chemotherapy. There were more patients with grade 0 toxicity (38.5% versus 5.6%, P = 0.06) and significantly less patients with grade 3 toxicity (0% versus 33.3%, P = 0.03) in the venlafaxine arm.
AE
There was no grade 3-4 AE related to venlafaxine. The main AE in arm A were grade 1-2 nausea and vomiting, asthenia or somnolence which were significantly more frequent than in arm B (Table 4 ). 
original articles Annals of Oncology discussion
The EFFOX trial is the first prospective randomized, doubleblind, placebo-controlled study evaluating a complementary treatment for prevention and relief of acute neurosensory symptoms of oxaliplatin. Despite the failure to reach the targeted accrual of patients, the study reached its primary end point with a significant reduction of patients experiencing acute neurologic toxicity in the venlafaxine arm.
The study was stopped before having reached the targeted number of patients. Key exclusion criteria such as no concomitant antidepressant treatment or no diabetes put a brake on inclusion. Investigators meetings also revealed that most clinicians were convinced of the effect of venlafaxine and became reluctant to go on with inclusions. Given this slow inclusion rate, we reached the expiry date of venlafaxine capsules, leading to the end of the trial. However, the superiority of venlafaxine over placebo was significant, even though we had an initial hypothesis requiring a higher number of inclusions.
The toxicity profile of venlafaxine was acceptable with no grade 3-4 adverse events. Grade 1-2 emesis was observed more frequently under venlafaxine, a finding consistent with the common side-effects of immediate release venlafaxine [19, 20] .
Hence, we assume that avoiding the initial administration of the 50-mg tablet could prevent vomiting at introduction of treatment. Extended release venlafaxine 37.5 mg should be started the night before chemotherapy instead.
Some other neuromodulatory agents have already been tested in patients with oxaliplatin-induced neurosensory toxicity. In a pilot, single-arm study, calcium gluconate and magnesium sulfate (Ca/Mg) infusions, prior and after oxaliplatin, seemed active against acute symptoms [21] . Unfortunately, the prospective evaluation of this treatment in the CONcePT trial was interrupted because of a lower tumor response rate in the Ca/Mg arm, founded on a planned review by the independent data monitoring committee [22] . According to an oral presentation of H. S. Hochster at the 2008 American Society of Clinical Oncology's Gastrointestinal meeting, it seems that there was no significant difference in response or time to first response. Published data remain awaited. Though, the available data of the CONcePT trial were analyzed; Ca/Mg salts decreased the incidence of chronic, cumulative sensory neuropathy but failed to demonstrate activity against acute neurotoxicity [23] .
A potential explanation for the efficacy of venlafaxine on oxaliplatin-induced neurosensory toxicity is a protective effect against oxaliplatin-induced oxidative stress. Indeed, preclinical models [24, 25] indicate that venlafaxine modulates the oxidative stress in the nervous system. On the other hand, there is growing evidence that oxaliplatin induces oxidative stress.
Hence, oxaliplatin-induced neurosensory toxicity is more frequent in patients with variant glutathione S-transferase (GSTP1) genotype ( 105 Ile homozygoty compared with 105 Val hetero-or homozygoty) [26] . GSTP1 plays a role in cellular response to oxidative stress, and previous studies [27] [28] [29] revealed that GSTP1 inhibits the stress-inducible c-Jun NH2-terminal kinase (JNK) signaling pathway. Whereas increased constitutive JNK activity leads to the up-regulation of specific downstream genes implicated in antioxidant cellular response, we hypothesize that the patients carrying GSTP1 Val protein could allow a higher activity of JNK, inducing the expression of genes involved in cellular defense, thereby protecting neuronal cells against chemotherapy-induced oxidative stress.
As a consequence, one might expect that antioxidants could contribute to reduce the neurosensory toxicity of oxaliplatin. In this range of ideas, Cascinu et al. [30] demonstrated in a single-arm phase II study the efficacy of glutathione to prevent oxaliplatin-induced neuropathy.
conclusions
In conclusion, this phase III trial confirms the clinical activity of venlafaxine for the symptom management of oxaliplatininduced acute neurotoxicity. Although these results, due to the small sample size, require further prospective studies, they may have immediate applications in the management of cancer patients under oxaliplatin-based chemotherapy. funding This work was promoted by EUREKA, an academic research association which received funds from Sanofi Aventis France for this trial. 
